Revision of PRECAUTIONS

Brimonidine tartrate
Brimonidine tartrate/brinzolamide
Ripasudil hydrochloride hydrate/brimonidine tartrate

June 11, 2024

Therapeutic category

Agents for ophthalmic use

Non-proprietary name

Brimonidine tartrate

Brimonidine tartrate/brinzolamide

Ripasudil hydrochloride hydrate/brimonidine tartrate

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision
8. IMPORTANT PRECAUTIONS (N/A)	8. IMPORTANT PRECAUTIONS <u>Corneal opacity with neovascularisation, etc. may occur following administration of this drug. Patients should consult their doctor periodically, and they should be carefully monitored. In addition, they should be adequately instructed to seek medical attention immediately if they have any subjective symptoms such as hyperaemia, reduced visual acuity, or blurred vision.</u>
11. ADVERSE REACTIONS (N/A)	11. ADVERSE REACTIONS <u>11.1 Clinically Significant Adverse Reactions</u> <u>Corneal opacity</u>

[References] Maruyama,Y.,et al.:Cornea 2017;36:1567-1569
Tsujinaka,A.,et al.:Acta Ophthalmol. 2019;97:e948-e949
Manabe,Y.,et al.:Eur.J.Ophthalmol. 2020;30:NP23-NP25
Chikama,T.,et al.:Ocul.Immunol.Inflamm. 2023;31:1842-1847

Note: Brimonidine tartrate is designated as a drug requiring preparation of a Drug Guide for Patients.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.